Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Chemotherapy regimens

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    787 result(s) found for: Chemotherapy regimens. Displaying page 6 of 40.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    EudraCT Number: 2017-000580-32 Sponsor Protocol Number: ARCADIA Start Date*: 2019-03-20
    Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"
    Full Title: Cabozantinib plus Ddurvalumab in patients with advanced and chemotherapy-treated bladder carcinoma, of urothelial and non-urothelial histology: an open-label, single-centre, phase 2, single-arm pro...
    Medical condition: Patients with metastatic urothelial carcinoma who have relapsed after =1 chemotherapy regimen
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10046714 Urothelial carcinoma bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-001144-39 Sponsor Protocol Number: GBMBIBT01 Start Date*: 2008-08-12
    Sponsor Name:Rigshospitalet
    Full Title: A randomized phase II trial with bevacizumab, irinotecan and cerebral radiotherapy versus bevacizumab, temozolomide and cerebral radiotherapy as first line treatment for patients with glioblastoma ...
    Medical condition: This study investigates first line experimental non-surgical therapy in patients with glioblastoma multiforme in good performance status
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018337 Glioblastoma multiforme LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-000684-85 Sponsor Protocol Number: PR-30-5010-C Start Date*: 2014-01-14
    Sponsor Name:TESARO UK Limited, (c/o Sisec Limited) [...]
    1. TESARO UK Limited, (c/o Sisec Limited)
    2. TESARO Inc
    Full Title: A phase III, randomized, open label, multicenter, controlled trial of niraparib versus physician’s choice in previously-treated, HER2 negative, germline BRCA mutation-positive breast cancer patients
    Medical condition: HER2 negative, BRCA germline mutated breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IS (Completed) HU (Completed) BE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) ES (Ongoing) PT (Completed) IT (Completed) FR (Completed) PL (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2010-021425-13 Sponsor Protocol Number: 212082PCR3001 Start Date*: 2011-02-10
    Sponsor Name:Janssen-Cilag International NV
    Full Title: An Open Label Study of Abiraterone Acetate in Subjects with Metastatic Castration-Resistant Prostate Cancer Who Have Progressed After Taxane-Based Chemotherapy
    Medical condition: Metastatic Castration-Resistant Prostate Cancer (PCR)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: CZ (Completed) HU (Completed) ES (Completed) IT (Completed) LT (Prematurely Ended) DK (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2017-001409-34 Sponsor Protocol Number: MO39171 Start Date*: 2017-11-20
    Sponsor Name:F. Hoffman-La Roche Ltd.
    Full Title: A PHASE III/IV, SINGLE ARM, MULTICENTER STUDY OF ATEZOLIZUMAB (TECENTRIQ) TO INVESTIGATE LONG-TERM SAFETY AND EFFICACY IN PREVIOUSLY-TREATED PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL C...
    Medical condition: Malignant neoplasm of bronchus and lung (nsc) adv.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed) SE (Completed) DK (Completed) LV (Completed) PL (Completed) GB (GB - no longer in EU/EEA) NL (Completed) ES (Ongoing) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-003644-40 Sponsor Protocol Number: MK-3475-199 Start Date*: 2016-06-06
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-199)
    Medical condition: Metastatic Castration-Resistant Prostate Cancer (mCRPC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FI (Completed) IE (Completed) DE (Completed) SE (Completed) ES (Completed) EE (Completed) NL (Completed) PL (Completed) FR (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-004331-23 Sponsor Protocol Number: 212082-PCR-2023 Start Date*: 2013-07-22
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized Phase 2 Study Evaluating Abiraterone Acetate With Different Steroid Regimens for Preventing Symptoms Associated With Mineralocorticoid Excess in Asymptomatic, Chemotherapy-Naïve and Me...
    Medical condition: Metastatic Castration-Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) BE (Completed) GB (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2021-003028-34 Sponsor Protocol Number: JAB-21822-1001 Start Date*: 2022-02-25
    Sponsor Name:Jacobio Pharmaceuticals Co., Ltd.
    Full Title: A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-21822 Monotherapy and Combination Therapy i...
    Medical condition: Phase 1: Advanced solid tumors, relapsed or refractory to standard therapy Phase 2: non-small cell lung cancer, metastatic colorectal cancer, and other solid tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) PL (Completed) HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-002428-33 Sponsor Protocol Number: SON-8184-1075 Start Date*: 2006-03-13
    Sponsor Name:SONUS Pharmaceuticals, Inc
    Full Title: A MULTICENTER PHASE 3, RANDOMIZED COMPARISON OF THE SAFETY AND EFFICACY OF WEEKLY TOCOSOL® PACLITAXEL VS. WEEKLY PACLITAXEL INJECTION IN THE TREATMENT OF METASTATIC BREAST CANCER
    Medical condition: METASTATIC BREAST CANCER (MBC)
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) SK (Prematurely Ended) HU (Prematurely Ended) ES (Ongoing) BE (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-003433-37 Sponsor Protocol Number: 213410 Start Date*: 2021-03-10
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A RANDOMIZED, OPEN-LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARLIMAB + DOCETAXEL TO DOSTARLIMAB + DOCETAXEL TO DOCETAXEL ALONE IN PARTICIPANTS WITH ADVANCED NON-SMALL CELL LUNG CANCER WHO HAV...
    Medical condition: Nonsmall Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned) SE (Trial now transitioned) NL (Trial now transitioned) RO (Trial now transitioned) GR (Trial now transitioned) BE (Trial now transitioned) FI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001182-87 Sponsor Protocol Number: UMCN-AKF16.01 Start Date*: 2017-01-10
    Sponsor Name:Radboud University Medical Centre
    Full Title: Pharmacokinetics of posaconazole (Noxafil(R)) as prophylaxis for invasive fungal disease
    Medical condition: prophylaxis for patients at high risk for invasive fungal diseases
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10017533 Fungal infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-006090-24 Sponsor Protocol Number: Ply26s Start Date*: 2007-02-23
    Sponsor Name:Plymouth Hospitals NHS Trust
    Full Title: A Parallel Randomised Phase II Trial of CHOP Chemotherapy With or Without Bortezomib in Relapsed Mantle Cell Lymphoma
    Medical condition: Relapsed, or refractory mantle cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026800 Mantle cell lymphoma recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-006790-33 Sponsor Protocol Number: AMLU1 - RV-AML-PI-401 Start Date*: 2009-04-27
    Sponsor Name:AZIENDA OSPEDALIERA CARDARELLI
    Full Title: A Phase II Study of Low dose ARA-C + Lenalidomide for Previously Untreated Non-M3 Acute Myeloid Leukemia (AML) without Deletion 5q in Patients Age 70 Years or Older Who Decline Remission Induction ...
    Medical condition: acute myeloid leukemia
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000838-36 Sponsor Protocol Number: PX104.1.7-201 Start Date*: 2004-09-20
    Sponsor Name:Pharmexa A/S
    Full Title: A Phase II trial evaluating the immunological and clinical efficay and safety of HER-2 Protein Autovac(TM) monotherapy in patients with metastatic breast cancer
    Medical condition: Female patients with histologically proven metastatic or locally advanced breast cancer who have HER-2 overexpression in the primary tumour and/or a metastatic lesion.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-004110-17 Sponsor Protocol Number: BO18414 Start Date*: 2005-03-29
    Sponsor Name:Roche Products Limited
    Full Title: Full title of the trial : An open-label, multicentre, dose-escalating phase I/II trial of 3-weekly rhuMAb 2H7 in patients with follicular non Hodgkin’s lymphoma
    Medical condition: follicular non-Hodgkin’s lymphoma (NHL)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2018-000618-39 Sponsor Protocol Number: Sym004-13 Start Date*: 2018-10-23
    Sponsor Name:Symphogen A/S
    Full Title: A Phase 2, Randomized, Open-Label, Multicenter, Three-Arm Trial of Sym004 versus each of its Component Monoclonal Antibodies, Futuximab and Modotuximab, in Patients with Chemotherapy-Refractory Met...
    Medical condition: Metastatic Colorectal Carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-006007-23 Sponsor Protocol Number: STH15195 Start Date*: 2009-12-15
    Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust
    Full Title: A clinicopathological phase II study of axitinib in patients with advanced angiosarcoma and other soft tissue sarcomas
    Medical condition: Soft tissue sarcoma
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-004981-42 Sponsor Protocol Number: GCTSK001 Start Date*: 2008-01-17
    Sponsor Name:Narodny onkologicky ustav
    Full Title: Phase II study of sunitinib malate (SUTENT®) in relapsed germ cell tumors in males.
    Medical condition: germ cell tumor
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: SK (Completed)
    Trial results: View results
    EudraCT Number: 2013-004606-26 Sponsor Protocol Number: OBF-13 Start Date*: 2014-04-07
    Sponsor Name:Med. Uni. Wien, Klinik f. Innere Med. I
    Full Title: Exploratory study investigating ocular blood flow in colorectal cancer patients before and after treatment with anti-angiogenic therapy
    Medical condition: metastatic colorectal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022681-27 Sponsor Protocol Number: O-DEX-1 Start Date*: 2010-11-09
    Sponsor Name:University Hospital Brno
    Full Title: Ofatumumab Added to Dexamethasone in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia
    Medical condition: Patients with refractory/relapsed CLL
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 19:54:43 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA